My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cassava Sciences, Inc. - Common Stock (NQ:SAVA)

2.990 -0.110 (-3.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cassava Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
38 39 Next >
Which stocks have an unusual volume on Thursday?
Let's have a look at the stocks with an unusual volume in today's session. 
Via Chartmill
Peraso Inc. (NASDAQ: PRSO) Regains Nasdaq Compliance, Earns $2.74 Price Target from Intro-act – More Stocks Inside
Via AB Newswire
In today's session, these stocks are experiencing unusual volume.
In today's session, these stocks are experiencing unusual volume. 
Via Chartmill
Cassava Sciences (SAVA) Soars 18% After CEO's Substantial Investment
Cassava Sciences (NASDAQ: SAVA) witnessed a dramatic surge in its stock price today, climbing an impressive 18% after its President and CEO, Richard Barry, disclosed a significant personal investment... 
Via MarketMinute
Topics Regulatory Compliance
Tuesday's session: top gainers and losers
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Keep an eye on the top gainers and losers in Tuesday's session.
Stay up-to-date with the latest market trends in the middle of the day on Tuesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
These stocks are gapping in today's session
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
Cassava Sciences (SAVA) Stock Is Surging Tuesday: What's Going On?
Cassava Sciences shares are trading higher Tuesday morning. A Form 4 filing disclosed that CEO Rick Barry acquired 237,941 shares at an average price of $2.25 each. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Why Super League Enterprise Shares Are Trading Higher By 200%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Curious about the stocks that are showing activity after the closing bell on Monday?
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Posts Q2 Loss on Pivot
Via The Motley Fool
Topics Intellectual Property
Cassava Reports Q2 2025 Financials Results and Provides Business Update
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Reports Q1 2025 Financials Results, Provides Business Update
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development
From Cassava Sciences, Inc.
Via GlobeNewswire
Top movers analysis one hour before the close of the markets on 2025-03-25: top gainers and losers in today's session.
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Cassava Sciences Stock Drops Over 30% After Alzheimer’s Drug Fails Study – But Retail Remains Hopeful
The drug showed no treatment benefit for patients in the study called REFOCUS-ALZ, the company said, while adding that the Alzheimer’s disease development program with Simufilam will be discontinued by... 
Via Stocktwits
Which stocks are experiencing notable movement on Tuesday?
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop
Cassava Sciences is ending simufilam development for Alzheimer's after Phase 3 trials failed. The company is shifting focus to potential seizure treatments. 
Via Benzinga
Which stocks are moving before the opening bell on Tuesday?
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
From Cassava Sciences, Inc.
Via GlobeNewswire
Tesla Rebounds While Tariffs Weigh On Manufacturing: What's Driving Markets Monday?
Stocks fell broadly on Monday to start the month of March with all three major indices red in midday trading. Investors digested a decline in February's ISM Manufacturing PMI data which fell to 50.3%,... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
38 39 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.